Literature DB >> 11311042

Spectrum of mutations in USH2A in British patients with Usher syndrome type II.

B P Leroy1, J A Aragon-Martin, M D Weston, D A Bessant, C Willis, A R Webster, A C Bird, W J Kimberling, A M Payne, S S Bhattacharya.   

Abstract

Usher syndrome (USH) is a combination of a progressive pigmentary retinopathy, indistinguishable from retinitis pigmentosa, and some degree of sensorineural hearing loss. USH can be subdivided in Usher type I (USHI), type II (USHII) and type III (USHIII), all of which are inherited as autosomal recessive traits. The three subtypes are genetically heterogeneous, with six loci so far identified for USHI, three for USHII and only one for USHIII. Mutations in a novel gene, USH2A, encoding the protein usherin, have recently been shown to be associated with USHII. The gene encodes a protein with partial sequence homology to both laminin epidermal growth factor and fibronectin motifs. We analysed 35 British and one Pakistani Usher type II families with at least one affected member, for sequence changes in the 20 translated exons of the USH2A gene, using heteroduplex analysis and sequencing. Probable disease-causing mutations in USH2A were identified in 15 of 36 (41.7%) Usher II families. The most frequently encountered mutation (11/15 families or 11/18 mutated alleles) was del2299G in exon 13, resulting in a frameshift and premature stop codon. Other mutations include insertions and point mutations, of which two are previously unreported. Five different polymorphisms were also detected. Our results indicate that mutations in this gene are responsible for disease in a large proportion of British Usher type II patients. Moreover, if screening for mutations in USH2A is considered, it is sensible to screen for the del2299G mutation first. Copyright 2001 Academic Press.

Entities:  

Mesh:

Year:  2001        PMID: 11311042     DOI: 10.1006/exer.2000.0978

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  14 in total

1.  Identification of 14 novel mutations in the long isoform of USH2A in Spanish patients with Usher syndrome type II.

Authors:  E Aller; T Jaijo; M Beneyto; C Nájera; S Oltra; C Ayuso; M Baiget; M Carballo; G Antiñolo; D Valverde; F Moreno; C Vilela; D Collado; H Pérez-Garrigues; A Navea; J M Millán
Journal:  J Med Genet       Date:  2006-11       Impact factor: 6.318

Review 2.  Antisense Oligonucleotides for the Treatment of Inner Ear Dysfunction.

Authors:  Michelle L Hastings; Timothy A Jones
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

3.  The USH2A c.2299delG mutation: dating its common origin in a Southern European population.

Authors:  Elena Aller; Lise Larrieu; Teresa Jaijo; David Baux; Carmen Espinós; Fernando González-Candelas; Carmen Nájera; Francesc Palau; Mireille Claustres; Anne-Françoise Roux; José M Millán
Journal:  Eur J Hum Genet       Date:  2010-02-10       Impact factor: 4.246

4.  Novel USH2A compound heterozygous mutations cause RP/USH2 in a Chinese family.

Authors:  Xiaowen Liu; Zhaohui Tang; Chang Li; Kangjuan Yang; Guanqi Gan; Zibo Zhang; Jingyu Liu; Fagang Jiang; Qing Wang; Mugen Liu
Journal:  Mol Vis       Date:  2010-03-17       Impact factor: 2.367

5.  Mutation analysis in the long isoform of USH2A in American patients with Usher Syndrome type II.

Authors:  Denise Yan; Xiaomei Ouyang; D Michael Patterson; Li Lin Du; Samuel G Jacobson; Xue-Zhong Liu
Journal:  J Hum Genet       Date:  2009-10-30       Impact factor: 3.172

6.  Development of a genotyping microarray for Usher syndrome.

Authors:  Frans P M Cremers; William J Kimberling; Maigi Külm; Arjan P de Brouwer; Erwin van Wijk; Heleen te Brinke; Cor W R J Cremers; Lies H Hoefsloot; Sandro Banfi; Francesca Simonelli; Johannes C Fleischhauer; Wolfgang Berger; Phil M Kelley; Elene Haralambous; Maria Bitner-Glindzicz; Andrew R Webster; Zubin Saihan; Elfride De Baere; Bart P Leroy; Giuliana Silvestri; Gareth J McKay; Robert K Koenekoop; Jose M Millan; Thomas Rosenberg; Tarja Joensuu; Eeva-Marja Sankila; Dominique Weil; Mike D Weston; Bernd Wissinger; Hannie Kremer
Journal:  J Med Genet       Date:  2006-09-08       Impact factor: 6.318

7.  Complete exon sequencing of all known Usher syndrome genes greatly improves molecular diagnosis.

Authors:  Crystel Bonnet; M'hamed Grati; Sandrine Marlin; Jacqueline Levilliers; Jean-Pierre Hardelin; Marine Parodi; Magali Niasme-Grare; Diana Zelenika; Marc Délépine; Delphine Feldmann; Laurence Jonard; Aziz El-Amraoui; Dominique Weil; Bruno Delobel; Christophe Vincent; Hélène Dollfus; Marie-Madeleine Eliot; Albert David; Catherine Calais; Jacqueline Vigneron; Bettina Montaut-Verient; Dominique Bonneau; Jacques Dubin; Christel Thauvin; Alain Duvillard; Christine Francannet; Thierry Mom; Didier Lacombe; Françoise Duriez; Valérie Drouin-Garraud; Marie-Françoise Thuillier-Obstoy; Sabine Sigaudy; Anne-Marie Frances; Patrick Collignon; Georges Challe; Rémy Couderc; Mark Lathrop; José-Alain Sahel; Jean Weissenbach; Christine Petit; Françoise Denoyelle
Journal:  Orphanet J Rare Dis       Date:  2011-05-11       Impact factor: 4.123

8.  A detailed clinical and molecular survey of subjects with nonsyndromic USH2A retinopathy reveals an allelic hierarchy of disease-causing variants.

Authors:  Eva Lenassi; Ajoy Vincent; Zheng Li; Zubin Saihan; Alison J Coffey; Heather B Steele-Stallard; Anthony T Moore; Karen P Steel; Linda M Luxon; Elise Héon; Maria Bitner-Glindzicz; Andrew R Webster
Journal:  Eur J Hum Genet       Date:  2015-02-04       Impact factor: 4.246

9.  Organophosphate retinopathy.

Authors:  Hang Pham; Michelle D Lingao; Anuradha Ganesh; Jenina E Capasso; Rosanne Keep; Karthikeyan A Sadagopan; Alex V Levin
Journal:  Oman J Ophthalmol       Date:  2016 Jan-Apr

10.  Generation and Genetic Correction of USH2A c.2299delG Mutation in Patient-Derived Induced Pluripotent Stem Cells.

Authors:  Xuezhong Liu; Justin Lillywhite; Wenliang Zhu; Zaohua Huang; Anna M Clark; Nicholas Gosstola; Colin T Maguire; Derek Dykxhoorn; Zheng-Yi Chen; Jun Yang
Journal:  Genes (Basel)       Date:  2021-05-25       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.